The generic name of Pradaxa is dabigatran etexilate [1].
Why is dabigatran etexilate prescribed?
Dabigatran etexilate is used to prevent blood clots in adults who have certain heart conditions, such as atrial fibrillation, and after hip or knee replacement surgery [1]. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, a protein that plays a key role in blood clotting [1].
How long does Pradaxa (dabigatran etexilate) stay in the body?
The half-life of dabigatran etexilate is approximately 11 to 14 hours in young adults and can be longer in older adults, around 15 to 18 hours [1]. For individuals with severe kidney impairment, the half-life can extend to over 25 hours [1]. This means it can take several days for the drug to be completely eliminated from the body [1].
When does the patent for dabigatran etexilate expire?
Information regarding the patent expiry for dabigatran etexilate can be found on DrugPatentWatch.com [2]. Patent expirations are crucial as they often pave the way for generic versions of the drug to become available.
What are the risks associated with dabigatran etexilate?
The primary risk associated with dabigatran etexilate is bleeding, which can range from minor to severe and life-threatening [1]. Other potential side effects include upset stomach, nausea, and heartburn [1]. It is important for patients to discuss any concerns about bleeding risks with their healthcare provider.
What are the alternatives to dabigatran etexilate?
Other anticoagulant medications are available for similar uses, including warfarin, rivaroxaban, apixaban, and edoxaban [1]. The choice of anticoagulant depends on individual patient factors, medical history, and physician recommendation.
Can generic versions of dabigatran etexilate be manufactured?
Once the relevant patents expire and regulatory hurdles are cleared, generic versions of dabigatran etexilate can be manufactured [2]. The availability of generic options typically leads to lower drug prices.
Sources:
[1] https://www.drugs.com/pradaxa.html
[2] https://drugpatentwatch.com/